Document is current
Any future updates will be listed below
-
Authors
Lanzer, Jan D. https://orcid.org/0000-0001-9373-2160
Valdeolivas, Alberto https://orcid.org/0000-0001-5482-9023
Pepin, Mark
Hund, Hauke
Backs, Johannes https://orcid.org/0000-0002-2322-2699
Frey, Norbert
Friederich, Hans-Christoph
Schultz, Jobst-Hendrik
Saez-Rodriguez, Julio https://orcid.org/0000-0002-8552-8976
Levinson, Rebecca T. https://orcid.org/0000-0002-2775-7543
-
Funding
Funding for this research was provided by:
Klaus Tschira Stiftung
Deutsche Forschungsgemeinschaft (Collaborative Research Center 1550 (SFB 1550, Molecular Circuits of Heart Disease))
Ruprecht-Karls-Universität Heidelberg
- License Information
-
More Information
Article History
Received: 30 December 2022
Accepted: 5 June 2023
First Online: 24 July 2023
Declarations
:
: The study was conducted in accordance with the Declaration of Helsinki. The ethics committee of the University Hospital Heidelberg approved this study (approval ID: S-571/2019).
: All authors provide consent for the publication of this manuscript.
: JSR has received funding from GSK and Sanofi and consultant fees from Travere Therapeutics. AV is currently employed by F. Hoffmann-La Roche Ltd.
